logo
NSDL nears listing deadline: How does the institutional giant measure up to CDSL's retail surge?

NSDL nears listing deadline: How does the institutional giant measure up to CDSL's retail surge?

Economic Times2 days ago
THE ECONOMIC TIMES NSDL is expected to start taking investor orders as early as next week, with the issue size scaled back to 5.01 crore shares from an earlier proposed 5.73 crore.
As India's largest depository heads for a SEBI-mandated IPO by July 31, investor focus sharpens on how NSDL compares to its listed peer CDSL, whose stock has surged 44% over the past year.National Securities Depository Ltd (NSDL), the country's oldest and largest depository by value of assets under custody, is nearing its much-anticipated stock market debut, with Securities and Exchange Board of India (Sebi) mandating a listing by the end of July.But while investors await clarity on the final date, comparisons with its nimbler rival Central Depository Services Ltd (CDSL) have come into sharp focus, especially after NSDL's unlisted shares corrected nearly 20% from their 52-week highs, even as CDSL's listed stock rallied 45% over the past 12 months.
According to Bloomberg, NSDL is expected to start taking investor orders as early as next week, with the issue size scaled back to 5.01 crore shares from an earlier proposed 5.73 crore. The IPO, which may raise up to $500 million, will be an entirely offer-for-sale (OFS) issue from shareholders including IDBI Bank, the National Stock Exchange of India, and State Bank of India. NSDL will not receive any proceeds from the IPO.
'The NSDL–CDSL divergence is a textbook case of differing business models and market positioning,' said Bhavik Joshi, Business Head at INVasset PMS. 'NSDL's core strength lies in its institutional dominance — with over 89% of India's demat asset value under custody, and deep integration with mutual funds, insurance firms, and government securities.'
Joshi said, 'It also holds a strong presence in the unlisted and pre-IPO ecosystem, which is poised for regulatory tailwinds as private market infrastructure evolves.'CDSL, by contrast, has emerged as a retail powerhouse, especially during the recent bull run. 'CDSL has emerged as the poster child for India's retail financialization. Its nimble tech stack, competitive pricing, and rapid onboarding have led to a dominant share of retail demat accounts,' said Joshi. 'Investors must distinguish between depth and breadth… CDSL, though more retail-centric and cyclical, may offer stronger operating leverage in upcycles.'
NSDL leads across several institutional metrics. As of December 31, 2024, it had 64,535 issuers, more than double CDSL's 31,557. It also had 63,542 DP Service Centres (DPSCs), compared to 17,883 for CDSL. NSDL continues to dominate in the unlisted space as well, with 53,169 unlisted companies on its platform, versus 21,295 for CDSL.In contrast, CDSL's strength lies in the number of demat accounts held, 14.65 crore as of December 2024, far outpacing NSDL's 3.88 crore. While CDSL holds more accounts, NSDL's custody value per account is significantly higher, averaging Rs 1.25 crore per account versus Rs 5 lakh for CDSL.In the unlisted market, NSDL shares have fallen from Rs 1,275 to around Rs 1,025 in recent weeks. 'The correction in NSDL's unlisted share price ahead of its IPO reflects recalibration rather than structural weakness,' said Joshi. 'It is not uncommon for pre-IPO valuations to adjust in response to listed peer benchmarks, changing market risk appetite, and revised growth expectations.''In NSDL's case, the re-pricing seems driven by three forces: softening investor expectations post-listing euphoria in CDSL, macro-level de-rating in tech-led financial infrastructure names, and the absence of a fresh primary capital infusion to signal near-term growth acceleration,' Joshi explained.Still, he believes the long-term outlook remains solid. 'If the IPO is priced conservatively relative to CDSL's current valuations, the drawdown may serve to reset expectations — not undermine fundamentals.'The IPO being entirely an OFS has also prompted questions about promoter intent. 'An IPO structured entirely as an Offer for Sale (OFS) naturally raises questions about promoter conviction and reinvestment intent,' Joshi said. 'While this doesn't inherently signal a lack of faith, it does alter the narrative.''NSDL is a cash-generating business with a long runway of regulatory and ecosystem-driven tailwinds. Its growth does not necessarily hinge on capital infusion,' he noted. However, in the absence of new capital, 'the spotlight shifts to governance quality, operating leverage, and dividend policy.'
NSDL has already informed shareholders that all pre-IPO equity shares will be locked in starting July 18, in line with Sebi norms. MUFG Intime India has been appointed as registrar, and ICICI Securities, Axis Capital, HSBC Holdings, and IDBI Capital are lead managers to the issue. CDSL's meteoric rise has raised concerns about whether valuations have overshot fundamentals. 'CDSL's rally over the past year mirrors the broader surge in retail market activity, a secular rise in demat account openings, and expanding use-cases for depositories across asset classes,' said Joshi.But he cautioned, 'A large part of CDSL's revenues remains market-linked — from corporate actions, transactions, and float income — all of which are susceptible to market cycles.''If the current rally is pricing in uninterrupted volume growth, record IPO flows, and a persistently bullish retail environment, then there is risk of overextension,' he said. Still, long-term structural drivers remain intact, including SEBI's push for dematerialisation and broader digital adoption.Looking beyond the listing, the medium-term growth opportunity for both depositories lies in expanding into new asset classes.'The next phase of growth for depositories lies beyond equity markets,' said Joshi. 'Medium-term opportunities include dematerialisation of insurance policies, educational certificates, sovereign gold bonds, and even tokenised assets.'CDSL is likely to benefit more from the ongoing expansion of the retail investor base, thanks to its quicker onboarding processes, wider integration with partners, and flexible tech architecture. NSDL, on the other hand, is better positioned to lead on the institutional front, particularly in managing complex asset classes and large-scale recordkeeping, owing to its long-standing relationships and institutional expertise, according to Joshi.
Also read | NSDL IPO set to open soon: Unlisted share price down 20% from peak. Here are 7 things to watch out for
'While CDSL has the retail velocity and brand recall, NSDL brings depth, trust, and compliance strength,' Joshi said. 'The growth runway is large enough for both to scale — but the market will reward whoever leads the transition from compliance infrastructure to financial infrastructure utility.'
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

It's not just Jane Street. Here's why derivatives are actually slowing down this July
It's not just Jane Street. Here's why derivatives are actually slowing down this July

Mint

time15 minutes ago

  • Mint

It's not just Jane Street. Here's why derivatives are actually slowing down this July

Derivative trading activity has noticeably slowed this month—a trend driven not just by the exit of aggressive US hedge fund Jane Street, but also by a sharp drop in market volatility, according to experts. With no price-moving triggers visible currently—think tariffs, fresh wars—and earnings mostly in line with expectations, traders have perched themselves on the fence, leading to lower volumes and a quieter market. In the first 13 trading days of July, the average daily premium turnover fell 20% on the BSE and 13% on the NSE compared to the same stretch in June, exchange data showed. Market regulator Sebi's (Securities and Exchange Board of India) interim Sebi order against Jane Street came on 3 July. Read more: Brokers push back as Sebi wages war on speculation According to Shrikant Chouhan, head of equity research at Kotak Securities, the impact of Jane Street's exit on derivative volumes could not exceed 10%. In the same 13-day period, the India VIX index fell 20%, indicating that the fall in average options premium turnover–total value of premiums paid on all options contracts–is not just because of the US prop desk firm. The India VIX measures expected market volatility over the next 30 days based on Nifty options prices. The index is currently at 11.98, reflecting subdued market sentiment. Calm on the Street Experts say the low volatility is because of no near-term event of tariff. Plus, earnings are on expected lines, which can keep volatility under control. 'Volumes have also come down with a neutral news flow, lacklustre Q1 earnings expectations, and no near-term triggers," Chouhan said. Dinesh Nagpal, a technical expert and a trader, said the world has come out of a major global turmoil after the US tariff situation and the Iran-Israel conflict. 'So, with no turmoil currently or expected in the near future, volatility tends to stay quiet," he said, adding that the Nifty index is also in a very narrow range for the same reason. To be sure, the Nifty50 has been trading in the 24,968-25,541 range in July. 'The market has become lethargic, almost addicted to a trigger and in the absence of that, it's just sideways," Nagpal said. Adapting to Jane Street's exit Some participants will have to change their trading strategies in order to adapt to an environment without Janes Street, a development that experts said will keep many traders on the sidelines. Rajesh Palviya, senior vice president, technical and derivatives research at Axis Securities, said Jane Street traders would typically take big positions on expiry days. Now in their absence, local players like HNIs, hedge funds, and high-frequency traders (HFTs) will have to change their strategies, he said. Read more: Retail investors are walking the wire. Sebi should let VCs join the show. 'The local players—whose strategies were designed to counter the kind of expiry-day moves that Jane Street was making—may be in a testing phase before taking big bets in the market," Palviya said, adding that trading volumes would pick up in a couple of months, once the participants gain confidence in their new strategies. Long July A long expiry month of July is another reason, with 31 July being a Thursday—Nifty contracts expire on the last Thursday of a month. 'This means that the extended window gives traders more time to react and adjust positions, leading to a stretched-out and a low-volatility phase in the earlier part of the month," Chouhan said. However, some of the drop in volumes in the derivative space is indeed because of Jane Street. Another F&O trader, speaking on condition of anonymity, said that due to Jane Street's exit, artificial price moves in the market have significantly reduced. Earlier, the firm's large-sized trades often led to random and abrupt price movements. 'With their absence, such distortions have largely disappeared, resulting in a much calmer and more orderly market environment, and reduced volatility also," this trader added. Preeti Chabra, founder at Trade Delta said that while some big players have exited and the volumes have dropped, the overall liquidity—without a huge price disruption—remains intact. 'This is because other market makers like HFTs continue to operate, providing the necessary depth and stability," she added. Read more: Financial distributors turn to GIFT City for outbound funds. But few can enter.

Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain
Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain

Time of India

time42 minutes ago

  • Time of India

Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain

Live Events Buyout groups Brookfield and EQT are in active discussions to buy Hyderabad-based Gland Pharma, a contract development and manufacturing organisation (CDMO) and injectables company, from China's Fosun Group in what could become one of the largest buyouts of the year in the segment, said people in the know. However, the galloping share price of Gland is a potential deal two private equity groups have been shortlisted after the initial round of bids earlier this such as CVC Capital Partners are also exploring a deal, said the people cited. Warburg Pincus is said to be weighing its options before taking a call, they Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 currently owns 51.8% of Gland, having pared its stake over the years. Market capitalisation has shot up to Rs 32,964.47 crore with the Gland Pharma stock appreciating 10% in the year to date in anticipation of a transaction. It closed Friday at Rs 2,000. In the past month alone, it has shot up 16%. The Fosun stake alone would require a payout of Rs 17,141.28 crore ($1.9 billion).Change of control will involve an open offer for an additional 26% of the company from minority shareholders, making it a much larger transaction. If the open offer is fully subscribed, it would translate to a Rs 25,711 crore ($3 billion) acquisition at current and Gland didn't respond to queries. Brookfield and EQT declined to investors are of the view the stock is overpriced and are interested only at a discount to the current level. 'There are macro headwinds because of industry glut and geopolitics,' said one of the people cited. 'Fosun has to decide if it is okay to sell at a significantly lower price.'This factor could be a deal breaker, analysts said. 'At this level, the process looks tough,' said another industry official. Fosun at various times in recent years, renewed its search for a strategic or financial deal for Gland Pharma. The company ran a full sale process last year but aborted it, only to revive plans earlier this summer, mandating Morgan Stanley and UBS. Mint was first to report that PE interest in Gland had revived in in 1978 by PVN Raju, Gland Pharma develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. As with other Chinese companies, Fosun has faced regulatory issues in India due to the frosty relationship between the two countries. Even its entry into India faced significant delays with deal contours needing tweaks to comply with FDI norms. Some experts said Fosun sees the timing as ideal for an exit. But with no success for years, Fosun has been selling down its shares in the public markets through block deals. Last year, it sold about 6% for ₹1,750 crore. 'The incremental growth for the company's base business in the US is likely to come at the cost of margins,' said Shyam Srinivasan of Goldman management is expecting Cenexi Group — a French injectables and CDMO company Gland acquired in 2023 — to break even by the December quarter. Gland has a toehold in Europe through Cenexi, but rebooting the organisation and its product mix has been analysts said Gland has a sound track record and its future prospects may attract buyers.A veteran industry expert said Gland Pharma has a 'strong compliance history' and its manufacturing quality is impeccable. Plus, a surge in demand is seen for large injectable capacities across the world, making it a good fit. Another strong push for Gland Pharma is the explosive growth in glucagon-like peptide-1(GLP-1) drugs for weight loss and diabetes. Novo Nordisk's Wegovy (semaglutide) is set to go off patent early next year in India and Canada, leading to a burst of generic variants expected to enter the market. This is likely to offset the current overcapacity of injectable assets around the world. Trade tensions between the US and China are adding to the interest in Indian contract manufacturing players for steady supplies. 'Although we have not seen any meaningful switching from China yet, such opportunities cannot be ruled out in the future,' an industry executive is also preparing for a larger play in the biologics business, focusing on expanding its biosimilar and biologic CDMO segment.'The company's collaboration with DRL (Dr Reddy's) and discussions with Henlius (of China) are progressing well, with revenue generation from DRL business expected from FY26,' it said in the presentation.

Two new campuses coming up, Ambedkar University set to shift from Kashmere Gate site
Two new campuses coming up, Ambedkar University set to shift from Kashmere Gate site

Indian Express

timean hour ago

  • Indian Express

Two new campuses coming up, Ambedkar University set to shift from Kashmere Gate site

With two new campuses under construction in Northwest Delhi's Dheerpur and Rohini, Ambedkar University Delhi (AUD) is set to relocate from its heritage campus in Kashmere Gate. While the Dheerpur campus, spanning 4.95 acres, is being developed at a cost of Rs 1,199.02 crore, the Rohini campus, spread across 20 acres, will be set up for a cost of Rs 1,107.56 crore, The Indian Express has learnt. Both projects received statutory clearances in 2022, and the construction is underway. Vice-Chancellor Anu Singh Lather said the move was necessitated by infrastructural limitations and long-term maintenance costs at the existing site. 'The university building that we are functioning out of is a very old heritage building. We have maintained it well, but we will have to move out of here soon,' said Lather. 'It will take at least a couple of years for the construction of the new campuses to end and for us to relocate.' The current campus at Lothian Road in Kashmere Gate sits on a 3-acre site housing a 400-year-old building complex. According to the university's website, it has 'well-stocked libraries, reading rooms, online journals and computer labs,' as well as 'classrooms equipped with audio-visual equipment and WiFi connectivity'. Hostel facilities are available only for women. In addition to Kashmere Gate, AUD has been operating a 6.5-acre campus in Karampura on Shivaji Marg since 2016-17. Originally housing Deen Dayal Upadhyaya College and before that Shivaji College, the Karampura campus has been retrofitted with modern infrastructure. 'The Karampura campus has all the facilities that the Kashmere Gate campus have — technology-enabled AC classrooms, library, computer labs, student activity areas, playgrounds and cafeteria,' the university website states. Currently, over 800 students study at Karampura campus, which is also home to the School of Global Affairs (since 2018), and is expected to house the School of Vocational Studies and the School of Law and Governance in the coming years. A training kitchen and restaurant have also been set up for students of tourism and hospitality programmes. Established in 2008 by the Delhi government, AUD focuses on the humanities and social sciences and is expanding to accommodate growing academic and infrastructural needs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store